1. Achtyes ED, Hopkins SC, Dedic N, Dworak H, Zeni C, Koblan K. Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia. Eur Arch Psychiatry Clin Neurosci 2023; 273: 1543–1556.
2.
Aleman A, Enriquez-Geppert S, Knegtering H, Dlabac-de Lange JJ. Moderate effects of noninvasive brain stimulation of the frontal cortex for improving negative symptoms in schizophrenia: Meta-analysis of controlled trials. Neurosci Biobehav Rev 2018; 89: 111–118.
3.
Anderson J, Ozan E, Chouinard V-A, Grant G, MacDonald A, Thakkar L et al. The Ketogenic Diet as a Transdiagnostic Treatment for Neuropsychiatric Disorders: Mechanisms and Clinical Outcomes. Curr Treat Options Psychiatry 2024; 12: 1.
4.
Arnovitz MD, Spitzberg AJ, Davani AJ, Vadhan NP, Holland J, Kane JM et al. MDMA for the Treatment of Negative Symptoms in Schizophrenia. J Clin Med 2022; 11: 3255.
5.
Bell M, Fiszdon J, Greig T, Wexler B, Bryson G. Neurocognitive enhancement therapy with work therapy in schizophrenia: 6-month follow-up of neuropsychological performance. J Rehabil Res Dev 2007; 44: 761–770.
6.
Bentsen H, Solberg DK, Refsum H, Bøhmer T. Clinical and biochemical validation of two endophenotypes of schizophrenia defined by levels of polyunsaturated fatty acids in red blood cells. Prostaglandins Leukot Essent Fatty Acids 2012; 87: 35–41.
7.
Bizzozero-Peroni B, Díaz-Goñi V, Jiménez-López E, Rodríguez-Gutiérrez E, Sequí-Domínguez I, Núñez de Arenas-Arroyo S et al. Daily Step Count and Depression in Adults: A Systematic Review and Meta-Analysis. JAMA Netw Open 2024; 7: e2451208.
8.
Bobes J, Arango C, Garcia-Garcia M, Rejas J. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study. J Clin Psychiatry 2010; 71: 280–286.
9.
Böge K, Hahne I, Bergmann N, Wingenfeld K, Zierhut M, Thomas N et al. Mindfulness-based group therapy for in-patients with schizophrenia spectrum disorders - Feasibility, acceptability, and preliminary outcomes of a rater-blinded randomized controlled trial. Schizophr Res 2021; 228: 134–144.
10.
Buckley PF, Miller BJ, Lehrer DS, Castle DJ. Psychiatric comorbidities and schizophrenia. Schizophr Bull 2009; 35: 383–402.
11.
Canul-Medina G, López-Pech G, Jiménez-Trejo F. Global research in schizophrenia and serotonin: a bibliometric analysis. Front Psychiatry 2024; 15: 1436906.
12.
Carbon M, Correll CU. Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia. CNS Spectr 2014; 19 Suppl 1: 38–52.
13.
Chambers NE, Michael Millett J, Moehle MS. The muscarinic M4 acetylcholine receptor exacerbates symptoms of movement disorders. Biochem Soc Trans 2023; 51: 691.
14.
Correll CU, Schooler NR. Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment. Neuropsychiatr Dis Treat 2020; 16: 519–534.
15.
Danan A, Westman EC, Saslow LR, Ede G. The Ketogenic Diet for Refractory Mental Illness: A Retrospective Analysis of 31 Inpatients Front Psychiatry 2022; 13: 951376.
16.
Dauwan M, Begemann MJH, Heringa SM, Sommer IE. Exercise Improves Clinical Symptoms, Quality of Life, Global Functioning, and Depression in Schizophrenia: A Systematic Review and Meta-analysis. Schizophr Bull 2016; 42: 588–599.
17.
Dlabac-de Lange JJ, Bais L, van Es FD, Visser BGJ, Reinink E, Bakker B et al. Efficacy of bilateral repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: results of a multicenter double-blind randomized controlled trial. Psychol Med 2015; 45: 1263–1275.
18.
Doğan Bulut S, Bulut S, Görkem Atalan D, Berkol T, Gürçay E, Türker T et al. The Relationship between Symptom Severity and Low Vitamin D Levels in Patients with Schizophrenia. PLoS ONE 2016; 11: e0165284.
19.
Espinoza S, Lignani G, Caffino L, Maggi S, Sukhanov I, Leo D et al. TAAR1 Modulates Cortical Glutamate NMDA Receptor Function. Neuropsychopharmacology 2015; 40: 2217–2227.
20.
Espinoza S, Salahpour A, Masri B, Sotnikova TD, Messa M, Barak LS et al. Functional interaction between trace amine-associated receptor 1 and dopamine D2 receptor. Mol Pharmacol 2011; 80: 416–425.
21.
Etchecopar-Etchart D, Korchia T, Loundou A, Llorca P-M, Auquier P, Lançon C et al. Comorbid Major Depressive Disorder in Schizophrenia: A Systematic Review and Meta-Analysis. Schizophr Bull 2020; 47: 298–308.
22.
Fatouros-Bergman H, Cervenka S, Flyckt, L, Edman G, Farde L. Meta-analysis of cognitive performance in drug-naïve patients with schizophrenia. Schizophr Res 2014; 158: 156–162.
23.
Favrod J, Nguyen A, Chaix J, Pellet J, Frobert L, Fankhauser C et al. Improving Pleasure and Motivation in Schizophrenia: A Randomized Controlled Clinical Trial. Psychother Psychosom 2019; 88: 84–95.
24.
Firth J, Stubbs B, Rosenbaum S, Vancampfort D, Malchow B, Schuch F et al. Aerobic Exercise Improves Cognitive Functioning in People With Schizophrenia: A Systematic Review and Meta-Analysis. Schizophr Bull 2017; 43: 546–556.
25.
Galderisi S, Mucci A, Bitter I, Libiger J, Bucci P, Fleischhacker WW et al. Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial. Eur Neuropsychopharmacol 2013; 23: 196–204.
26.
Grant PM, Bredemeier K, Beck AT. Six-Month Follow-Up of Recovery-Oriented Cognitive Therapy for Low-Functioning Individuals With Schizophrenia. Psychiatr Serv Wash DC 2017; 68: 997–1002.
27.
Grant PM, Huh GA, Perivoliotis D, Stolar NM, Beck AT. Randomized trial to evaluate the efficacy of cognitive therapy for low-functioning patients with schizophrenia. Arch Gen Psychiatry 2012; 69: 121–127.
28.
Hadryś T, Rymaszewska J. Amisulpride – is it as all other medicines or is it different? An update. Psychiatr Pol 2020; 54: 977–989.
29.
Hong H, Donlon J, Schaefer M, Sarkar S, Bugarski-Kirola D, Shad MU et al. Memantine for the Treatment of Primary Negative Symptoms in Schizophrenia: A Meta-analysis of Randomized Controlled Trials. Clin Drug Investig 2025.
30.
Huang M-L, Chen M-C. Effectiveness of Walking Exercise in Improving Physical Fitness and Depression in Patients With Schizophrenia. Biol Res Nurs 2025; 27: 229–235.
31.
Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet Lond Engl 2019; 394: 939–951.
32.
Jääskeläinen E, Juola P, Hirvonen N, McGrath JJ, Saha S, Isohanni M et al. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull 2013; 39: 1296–1306.
33.
Kantrowitz JT, Malhotra AK, Cornblatt B, Silipo G, Balla A, Suckow RF et al. High dose D-serine in the treatment of schizophrenia. Schizophr Res 2010; 121: 125–130.
34.
Kelly DL, Lee CM, Roche DJO, Talor MV, Clark S, Eaton WW. Randomized Double Blind Inpatient Study of a Gluten-Free Diet in Persons with Schizophrenia. MedRxiv Prepr Serv Health Sci 2025; 2025.02.24.25322813.
35.
Koziej S, Kowalczyk E, Soroka E. Cariprazine in Psychiatry: A Comprehensive Review of Efficacy, Safety, and Therapeutic Potential. Med Sci Monit Int Med J Exp Clin Res 2024; 30: e945411-1-e945411-7.
36.
Larsen LQ, Schnor H, Tersbøl BP, Ebdrup BH, Nordsborg NB, Midtgaard J. The impact of exercise training complementary to early intervention in patients with first-episode psychosis: a qualitative sub-study from a randomized controlled feasibility trial. BMC Psychiatry 2019; 19: 192.
37.
Leutwyler H, Hubbard EM, Jeste DV, Miller B, Vinogradov S. Associations of schizophrenia symptoms and neurocognition with physical activity in older adults with schizophrenia. Biol Res Nurs 2014; 16: 23–30.
38.
Longhitano C, Finlay S, Peachey I, Swift J-L, Fayet-Moore F, Bartle T et al. The effects of ketogenic metabolic therapy on mental health and metabolic outcomes in schizophrenia and bipolar disorder: a randomized controlled clinical trial protocol. Front Nutr 2024; 11: 1444483.
39.
Maurus I, Roell L, Lembeck M, Papazova I, Greska D, Muenz S et al. Exercise as an add-on treatment in individuals with schizophrenia: Results from a large multicenter randomized controlled trial. Psychiatry Res 2023; 328: 115480.
40.
McCutcheon RA, Reis Marques T, Howes OD. Schizophrenia-An Overview. JAMA Psychiatry 2020; 77: 201–210.
41.
Melle I, Larsen TK, Haahr U, Friis S, Johannesen JO, Opjordsmoen S et al. Prevention of negative symptom psychopathologies in first-episode schizophrenia: two-year effects of reducing the duration of untreated psychosis. Arch Gen Psychiatry 2008; 65: 634–640.
42.
Momtazmanesh S, Zare-Shahabadi A, Rezaei N. Cytokine Alterations in Schizophrenia: An Updated Review. Front Psychiatry 2019; 10: 892.
43.
Mosolov SN, Yaltonskaya PA. Primary and Secondary Negative Symptoms in Schizophrenia. Front Psychiatry 2022; 12: 766692.
44.
Mulligan LD, Varese F, Harris K, Haddock, G. Alcohol use and suicide-related outcomes in people with a diagnosis of schizophrenia: a comprehensive systematic review and meta-analysis. Psychol Med 2024; 54: 1–12.
45.
Murthy V, Hanson E, DeMartinis N, Asgharnejad M, Dong C, Evans R et al. INTERACT: a randomized phase 2 study of the DAAO inhibitor luvadaxistat in adults with schizophrenia. Schizophr Res 2024; 270: 249–257.
46.
Myken AN, Ebdrup BH, Sørensen ME, Broberg BV, Skjerbæk MW, Glenthøj BY et al. Lower Vitamin C Levels Are Associated With Less Improvement in Negative Symptoms in Initially Antipsychotic-Naïve Patients With First-Episode Psychosis. Int J Neuropsychopharmacol 2022; 25: 613–618.
47.
Nasim R, Nawaz S, Nasim MT. The Effects of Antipsychotic Drugs and Non-Pharmacological Therapies on Schizophrenia. Targets 2025; 3: 10.
48.
Olfson M, Stroup TS, Huang C, Wall MM, Crystal S, Gerhard T. Suicide Risk in Medicare Patients With Schizophrenia Across the Life Span. JAMA Psychiatry 2021; 78: 876–885.
49.
Orsi JA, Malinowski FRL, Kagan S, Weingarten R, Villares CC, Bressan RA et al. Evaluation of Ongoing Participation of People with Schizophrenia in a Mutual Support Group as a Complementary Intervention to Outpatient Psychiatric Treatment. Psychiatr Q 2021; 92: 1283–1296.
50.
Osugo M, Whitehurst T, Shatalina E, Townsend L, O'Brien O, Mak TLA et al. Dopamine partial agonists and prodopaminergic drugs for schizophrenia: Systematic review and meta-analysis of randomized controlled trials. Neurosci Biobehav Rev 2022; 135: 104568.
51.
Palmer CM, Gilbert-Jaramillo J, Westman EC. The ketogenic diet and remission of psychotic symptoms in schizophrenia: Two case studies. Schizophr Res 2019; 208: 439–440.
52.
Palmer ER, Griffiths SL, Watkins B, Weetman T, Ottridge R, Patel S et al. Antidepressants for the prevention of depression following first-episode psychosis (ADEPP): study protocol for a multi-centre, double-blind, randomised controlled trial. Trials 2023; 24: 646.
53.
Patel R, Jayatilleke N, Broadbent M, Chang C-K, Foskett N, Gorrell G. et al. Negative symptoms in schizophrenia: a study in a large clinical sample of patients using a novel automated method. BMJ Open 2015; 5 (9): e007619.
54.
Pawełczyk T, Grancow-Grabka M, Kotlicka-Antczak M, Trafalska E, Pawełczyk A. A randomized controlled study of the efficacy of six-month supplementation with concentrated fish oil rich in omega-3 polyunsaturated fatty acids in first episode schizophrenia. J Psychiatr Res 2016; 73: 34–44.
55.
Puranen A, Koponen M, Lähteenvuo M, Tanskanen A, Tiihonen J, Taipale H. Real-world effectiveness of antidepressant use in persons with schizophrenia: within-individual study of 61,889 subjects. Schizophrenia 2023; 9: 1–5.
56.
Rabinowitz J, Levine SZ, Garibaldi G, Bugarski-Kirola D, Berardo CG, Kapur S. Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data. Schizophr Res 2012; 137: 147–150.
57.
Ramey OL, Silva Almodóvar A. Xanomeline-Trospium: A Novel Therapeutic for the Treatment of Schizophrenia. Ann Pharmacother 2025; 59: 937–950.
58.
Rossi A, Galderisi S, Rocca P, Bertolino A, Rucci P, Gibertoni D et al. Personal resources and depression in schizophrenia: The role of self-esteem, resilience and internalized stigma. Psychiatry Res 2017; 256: 359–364.
59.
Rybakowski F, Drews K. The influence of physical activity on cognitive functions in patients suffering from schizophrenia. Neuropsychiatr Neuropsychol 2018; 12: 170–175.
60.
Samochowiec J, Szulc A, Bieńkowski P, Dudek D, Gałecki P, Heitzman J et al. Polish Psychiatric Association consensus statement on non-pharmacological methods in the treatment of negative symptoms of schizophrenia. Psychiatr Pol 2021; 55: 719–742.
61.
Sarris J, Ravindran A, Yatham LN, Marx W, Rucklidge JJ, McIntyre RS et al. Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce. World J Biol Psychiatry 2022; 23: 424–455.
62.
Schuch FB, Stubbs B, Meyer J, Heissel A, Zech P, Vancampfort D et al. Physical activity protects from incident anxiety: A meta-analysis of prospective cohort studies. Depress Anxiety 2019; 36: 846–858.
63.
Schuch FB, Vancampfort D, Firth J, Rosenbaum S, Ward PB, Silva ES et al. Physical Activity and Incident Depression: A Meta-Analysis of Prospective Cohort Studies. Am J Psychiatry 2018; 175: 631–648.
64.
Schuster T, Riesbeck M, Kamp D, Gaebel W, Falkai P, Hasan A et al. Providing Cognitive Remediation Therapy to People with Schizophrenia: Results of a Survey in Psychiatric Clinics in Germany. Fortschr Neurol Psychiatr 2024.
65.
Seeman MV. Schizophrenia Mortality: Barriers to Progress. Psychiatr Q 2019; 90: 553–563.
66.
Siskind D, Orr S, Sinha S, Yu O, Brijball B, Warren N et al. Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis. Br J Psychiatry J Ment Sci 2020; 220: 115–120.
67.
Siwek M, Wojtasik-Bakalarz K, Krupa AJ, Chrobak AA. Brexpiprazole—Pharmacologic Properties and Use in Schizophrenia and Mood Disorders. Brain Sci 2023; 13: 397.
68.
Smith RC, Boules S, Mattiuz S, Youssef M, Tobe RH, Sershen H et al. Effects of transcranial direct current stimulation (tDCS) on cognition, symptoms, and smoking in schizophrenia: A randomized controlled study. Schizophr Res 2015; 168: 260–266.
69.
Sönmez N, Romm KL, Østefjells T, Grande M, Jensen LH, Hummelen B et al. Cognitive behavior therapy in early psychosis with a focus on depression and low self-esteem: A randomized controlled trial. Compr Psychiatry 2020; 97.
70.
Tan X, Martin D, Lee J, Tor PC. The Impact of Electroconvulsive Therapy on Negative Symptoms in Schizophrenia and Their Association with Clinical Outcomes. Brain Sci 2022; 12: 545.
71.
Tseng P-T, Zeng B-S, Hung C-M, Liang C-S, Stubbs B, Carvalho AF et al. Assessment of Noninvasive Brain Stimulation Interventions for Negative Symptoms of Schizophrenia: A Systematic Review and Network Meta-analysis. JAMA Psychiatry 2022; 79: 770–779.
72.
Turner DT, McGlanaghy E, Cuijpers P, van der Gaag M, Karyotaki E, MacBeth A. A Meta-Analysis of Social Skills Training and Related Interventions for Psychosis. Schizophr Bull 2018; 44: 475–491.
73.
van Zonneveld SM, Haarman BCM, van den Oever EJ, Nuninga JO, Sommer IEC. Unhealthy diet in schizophrenia spectrum disorders. Curr Opin Psychiatry 2022; 35: 177–185.
74.
Vancampfort D, Firth J, Schuch FB, Rosenbaum S, Mugisha J, Hallgren M et al. Sedentary behavior and physical activity levels in people with schizophrenia, bipolar disorder and major depressive disorder: a global systematic review and meta-analysis. World Psychiatry 2017; 16 (3): 308-315.
75.
Vetrani C, DE Simone G, Saia V, Barrea L, Muscogiuri G, Graziadio C et al. Diet quality in patients with treatment-resistant schizophrenia: time for improving nutritional recommendations. Minerva Endocrinol 2024.
76.
Wieczorek T, Kobyłko A, Stramecki F, Fila-Witecka K, Beszłej J, Jakubczyk M et al. Transcranial magnetic stimulation (TMS) in treatment of psychiatric disorders - review of current studies. Psychiatr Pol 2021; 55: 565–583.
77.
Wójciak P, Domowicz K, Zabłocka M, Michalak M, Rybakowski JK. Association of Negative Symptoms of Schizophrenia Assessed by the BNSS and SNS Scales With Neuropsychological Performance: A Gender Effect. Front Psychiatry 2021; 12: 797386.
78.
Zipursky RB, Menezes NM, Streiner DL. Risk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review. Schizophr Res 2014; 152: 408–414.
